Dr. Wen’s background is across pharmaceutical engineering, cheminformatics, and computer science. Over the past few decades, he has led and taken part in over ten research projects associated with the National Natural Science Foundation of China. Dr. Wen’s research is mainly focused on developing gene expression-based models for clinical prediction and toxicogenomics for facilitating drug safety evaluation. Specifically, he first developed a centralized web-based application for drug-induced adverse drug reactions (Drug-Induced Rhabdomyolysis Atlas (DIRA, www.adratlas.com/dira)/Drug-Induced QT Prolongation Atlas (DIQTA, www.adratlas.com/diqta)) and provided a one-stop solution to query/download drug information for mechanism studies and predictive model development, which has greatly facilitated idiosyncratic ADR research and improved drug attrition. His interests widely cover (1) the development of knowledge-based centralized databases for drug safety evaluation; (2) the development and application of a standard pipeline for genomic data (e.g., microarray/NGS) analysis for drug safety and efficacy questions; (3) the development and application of gene expression-based models in tumorigenesis for clinical prediction; (4) and the development and application of machine learning algorithms in pharmacogenomics. Dr. Wen has published more than 30 papers in prestigious journals with a total of more than 500 citations.
Dr. Wen’s background is across pharmaceutical engineering, cheminformatics, and computer science. Over the past few decades, he has led and taken part in over ten research projects associated with the National Natural Science Foundation of China. Dr. Wen’s research is mainly focused on developing gene expression-based models for clinical prediction and toxicogenomics for facilitating drug safety evaluation. Specifically, he first developed a centralized web-based application for drug-induced adverse drug reactions (Drug-Induced Rhabdomyolysis Atlas (DIRA, www.adratlas.com/dira)/Drug-Induced QT Prolongation Atlas (DIQTA, www.adratlas.com/diqta)) and provided a one-stop solution to query/download drug information for mechanism studies and predictive model development, which has greatly facilitated idiosyncratic ADR research and improved drug attrition. His interests widely cover (1) the development of knowledge-based centralized databases for drug safety evaluation; (2) the development and application of a standard pipeline for genomic data (e.g., microarray/NGS) analysis for drug safety and efficacy questions; (3) the development and application of gene expression-based models in tumorigenesis for clinical prediction; (4) and the development and application of machine learning algorithms in pharmacogenomics. Dr. Wen has published more than 30 papers in prestigious journals with a total of more than 500 citations.